Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM PeptideLibraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Once more unto the (data) breachGo to article: In this issueGo to article: ContentsGo to article: SHL MedicalGo to article: SHL Medical Company Insight Go to article: Datwyler Company InsightGo to article: DatwylerGo to article: LabcorpGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BaxterGo to article: Sukano Company InsightGo to article: SukanoGo to article: CommentGo to article: Use of off-label therapies increases the need for reliable clinical trial dataGo to article: Unmet needs remain in the neuroendocrine tumour treatment paradigmGo to article: Drinking alcohol raises risk of oesophageal and other cancersGo to article: Verder Company InsightGo to article: VerderGo to article: RegPakGo to article: Avery DennisonGo to article: In DepthGo to article: Pharma cybersecurity breaches to know and learn fromGo to article: The drugs treating alcoholism Go to article: In with the old: how an established vaccine is fuelling Covid-19 treatmentGo to article: How are hospitals tackling pharmaceutical pollution?Go to article: After Covid-19, mRNA technology aims to revolutionise the flu shotGo to article: Pushing for a UK genomics revolutionGo to article: MicronovaGo to article: Pfeiffer VacuumGo to article: HOF SonderanlagenbauGo to article: In DataGo to article: Data: pharma subsidiaries Go to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue